NeoGenomics, Inc. — Q1 2015 Form 10-Q
Business and period: Unaudited results for the three months ended March 31, 2015. NeoGenomics operates cancer-focused clinical diagnostic laboratories offering genetic, molecular, and pathology testing. Comparisons are with the three months ended March 31, 2014; amounts below are in millions except per-share data and where noted.
Financial performance and liquidity
| Metric | Q1 2015 | Q1 2014 |
|---|---|---|
| Revenue | $23.0 | $18.2 |
| Gross profit / gross margin | $9.5 / 41.4% | $8.7 / 47.9% |
| Operating expenses | $10.1 | $8.3 |
| Operating income (loss) | $(0.6) | $0.4 |
| Net income (loss) | $(0.8); $(0.01) per share | $0.1; $0.00 per share |
| Adjusted EBITDA (non-GAAP) | $1.5 | $1.7 |
| Operating cash flow | $(0.8) | $1.0 |
Cash and cash equivalents were $31.2 at March 31, 2015, down $2.4 since year-end. Working capital was $43.5. Capital expenditures were $0.8; financing cash use was $0.8, primarily lease repayments. Equipment capital lease obligations totaled $10.1 ($3.8 current and $6.3 long-term). Management reported no revolving-credit advances in the quarter and said the facility had been paid off. The filing reports no separate conventional debt balance.
Material changes and management commentary
- Revenue increased 27% year over year. Path Logic, acquired in July 2014, contributed $2.3; management reported 14% organic growth in the Base Business. Base Business requisitions rose 27.0% and tests performed rose 27.5%.
- Base Business average revenue per test fell 10.8%, primarily reflecting 2015 Medicare fee reductions for certain FISH and immunohistochemistry codes and similar commercial payer reductions. Management expected the reimbursement impact to continue through 2015.
- Gross margin declined to 41.4% from 47.9%. Base Business cost per test improved 3.5%, but average gross profit per test fell 18.7% as lower reimbursement outweighed efficiency gains. Path Logic’s gross margin was 22.0% for the quarter.
- Management attributed the net loss to cost growth and reimbursement pressure, while noting lower bad-debt expense and improved collections. It expected continued revenue growth and lower cost per test to reduce losses in coming quarters; this was not formal numerical earnings guidance.
- Operating cash flow turned negative, primarily due to the net loss, higher receivables, and payments of liabilities. Management noted that first-quarter receivables typically rise as patients have not yet met annual deductibles. At March 31, 32% of gross receivables were over 120 days past due; the allowance for doubtful accounts was $4.1, or 16% of gross receivables.
- Management forecast approximately $8.0–$9.5 of capital expenditures over the next year, funded through cash, capital leases, and bank loan facilities. It also highlighted new test launches, including a 315-gene solid-tumor profile, and planned an unrestricted commercial launch of its NeoLAB prostate test in the second half of 2015, subject to further validation.
Risks, contingencies, and unusual items
- Key disclosed risks include reimbursement reductions, payer collection and billing accuracy, regulatory requirements (including CLIA and potential FDA regulation of laboratory-developed tests), competition, scaling operations, and integration of acquisitions.
- The filing says ordinary-course legal proceedings were not considered material; it reports no material proceedings terminated during the quarter. Management stated disclosure controls were effective at a reasonable assurance level.
- On May 4, 2015, the board added 2.5 million shares to the equity plan and granted 1.645 million options at $4.78 per share. The company estimated associated compensation expense increases of approximately $1.2 million in each of 2015 and 2016, $0.5 million in 2017, and $0.1 million in 2018.
Investor verification points
- Track realized reimbursement and revenue per test against volume growth, particularly for FISH and immunohistochemistry.
- Monitor gross-margin recovery, cost per test, and whether management’s expected loss reduction materializes.
- Assess receivables aging, collections, and operating cash flow given the substantial over-120-day balance and first-quarter cash use.
- Verify planned capital spending, lease obligations, and the dilution and compensation expense from the May option grants.